Pacific Biosciences of California, Inc.
PACBNASDAQHealthcare● Active
$1.38
$-0.07(-4.83%)
Market Cap$428630329
P/E Ratio—
52W High$2.73
52W Low$0.99
Pacific Biosciences of California, Inc. (PACB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PACB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.12
Est. -$0.17 · +29.4%
Revenue
$0.04B
Est. $0.04B · -6.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 8-Quarter EPS Beat Streak
PACB reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2027 | Feb 9, 2027 | -$0.13 | — | — | — | $0.05B | — |
| ◌ Q4 FY2026 | Nov 3, 2026 | -$0.13 | — | — | — | $0.04B | — |
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.13 | — | — | — | $0.04B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.17 | -$0.12 | +29.4% | $0.04B | $0.04B | -6.9% |
| ▲ Q1 FY2026 | Feb 12, 2026 | -$0.19 | -$0.12 | +36.8% | $0.04B | $0.04B | +3.7% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.16 | -$0.12 | +25.0% | $0.04B | $0.04B | -13.8% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.18 | -$0.13 | +27.8% | $0.04B | $0.04B | -0.5% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.19 | -$0.15 | +21.1% | $0.04B | $0.04B | +0.7% |
Q1 FY2027
Feb 9, 2027
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Q4 FY2026
Nov 3, 2026
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.12
EPS Est.
-$0.17
EPS Surpr.
+29.4%
Revenue
$0.04B
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
-$0.12
EPS Est.
-$0.19
EPS Surpr.
+36.8%
Revenue
$0.04B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.16
EPS Surpr.
+25.0%
Revenue
$0.04B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.18
EPS Surpr.
+27.8%
Revenue
$0.04B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$0.19
EPS Surpr.
+21.1%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q3 FY2028 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q2 FY2028 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q1 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q4 FY2027 | $-0.12 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.12 | $-0.12 | $-0.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.0B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +29.4% | $1.71 | $1.65 | -3.51% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +36.8% | $1.84 | $1.84 | +0.00% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +25.0% | $2.00 | $1.92 | -4.00% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +27.8% | $1.38 | $1.26 | -8.70% |
| ▲ Q2 FY2025 | May 8, 2025 | +21.1% | $1.13 | $1.20 | +6.19% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +0.0% | $1.36 | $1.48 | +8.82% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +0.0% | $2.65 | $2.45 | -7.55% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +16.7% | $1.60 | $1.53 | -4.38% |
Q2 FY2026-3.51%
Report Date
May 7, 2026
EPS Beat/Miss
+29.4%
Price Before
$1.71
Price After
$1.65
Q1 FY2026+0.00%
Report Date
Feb 12, 2026
EPS Beat/Miss
+36.8%
Price Before
$1.84
Price After
$1.84
Q4 FY2025-4.00%
Report Date
Nov 5, 2025
EPS Beat/Miss
+25.0%
Price Before
$2.00
Price After
$1.92
Q3 FY2025-8.70%
Report Date
Aug 7, 2025
EPS Beat/Miss
+27.8%
Price Before
$1.38
Price After
$1.26
Q2 FY2025+6.19%
Report Date
May 8, 2025
EPS Beat/Miss
+21.1%
Price Before
$1.13
Price After
$1.20
Q1 FY2025+8.82%
Report Date
Feb 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.36
Price After
$1.48
Q4 FY2024-7.55%
Report Date
Nov 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$2.65
Price After
$2.45
Q3 FY2024-4.38%
Report Date
Aug 7, 2024
EPS Beat/Miss
+16.7%
Price Before
$1.60
Price After
$1.53
Avg Beat Reaction-1.64%
Beat Rate8 / 8 quarters
Largest Move+8.82% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PACB ends December
Pacific Biosciences of California, Inc. (PACB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.12 — beating the analyst consensus of $-0.17 by +29.4%. PACB has beaten EPS estimates for 8 consecutive quarters. The next PACB earnings date is expected around September 1, 2026.
Each quarter, investors track PACB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PACB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PACB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PACB earnings · 5 questionsPacific Biosciences of California, Inc.'s next earnings report is expected around September 1, 2026. PACB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PACB historically reports after market close (AMC).
PACB earnings datewhen is PACB earningsPACB next earnings datewhen does PACB report earningsPACB earnings calendar
▸ Source: FMP · Pacific Biosciences of California, Inc. SEC filings · US GAAP · Pacific Biosciences of California, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026